Hemangiosarcoma in Dogs: the silent killer, and why it is so hard to treat.

What hemangiosarcoma is

Hemangiosarcoma (often shortened to HSA) is a cancer of the cells that line blood vessels. Because blood vessels run everywhere in the body, the tumor can start almost anywhere, but in dogs it shows up most often in the spleen, the heart, the liver, and the skin. It is most common in middle-aged and older large-breed dogs, and some breeds, especially Golden Retrievers and German Shepherds, are hit harder than others.

Two features make it uniquely dangerous. First, because it is built from blood-vessel cells, an HSA tumor is essentially a fragile, blood-filled sac. It can rupture and bleed internally, sometimes catastrophically and without notice. Second, it spreads early and readily through the bloodstream, so by the time it is found there are often already microscopic deposits elsewhere in the body that no scan can see.

This post focuses on splenic hemangiosarcoma, the most common form and the one nearly all of the treatment research is based on. Cancers of the heart and other sites behave differently and we will return to them later in the series.

Why it is called the silent killer

Most cancers announce themselves with a lump you can feel or a symptom that builds over weeks. Hemangiosarcoma usually does neither. A tumor can grow inside the spleen for a long time while the dog looks and acts completely healthy. Owners frequently describe a dog that was normal one day and collapsed the next.

What is actually happening is often a sudden internal bleed. The tumor ruptures, blood pools in the abdomen, and the dog becomes weak, pale, or collapses. Sometimes the bleed stops on its own and the dog seems to recover, which is part of what makes the disease so cruel, because that temporary recovery can delay the trip to the vet. By the time hemangiosarcoma is diagnosed, it is frequently already advanced.

The standard of care: surgery, then chemo

For a bleeding splenic tumor, the first step is almost always surgery to remove the spleen, an operation called a splenectomy. It does two jobs at once: it stops the bleeding, which is an immediate, life-threatening emergency, and it removes the primary tumor. Surgery is genuinely valuable here. Many dogs go home and feel well afterwards.

The problem is what surgery cannot do. Removing the spleen does nothing about the cancer cells that have already traveled elsewhere. That is why oncologists usually add chemotherapy after surgery, most commonly a drug called doxorubicin, to try to slow those hidden deposits. The honest question is how much time that combination actually buys. The answer is where the numbers get sobering.

The hard numbers

Let us start with the single most important figure. In the largest careful study of this question, according to PubMed, dogs treated with splenectomy alone had a median survival of just 1.6 months (Wendelburg et al., Journal of the American Veterinary Medical Association, 2015, a review of 208 dogs). Median means half the dogs had died by that point. Surgery buys comfort and stops the bleeding, but on its own it does not buy much time.

Chemotherapy does help, but less than most people hope. In a study of 59 dogs with splenic hemangiosarcoma, according to PubMed, adding chemotherapy after surgery raised median survival from 86 days to 144 days (Kim et al., Journal of the American Veterinary Medical Association, 2007). In plain terms, roughly three months became roughly five.

What adding chemotherapy buys

Median survival, splenic hemangiosarcoma: surgery alone vs. surgery plus chemotherapy

That gain is real, and it is worth having. It is also, honestly, close to the ceiling of the standard playbook. What makes the number trustworthy is that four independent studies, run by different teams, all land in the same place:

The same story across four studies: surgery buys weeks to a couple of months, and chemotherapy adds a few more. The numbers differ mainly because each study enrolls a different mix of disease stages.

Why chemotherapy hits a ceiling

It is worth understanding why more chemo does not simply equal more time. The Wendelburg study looked closely at this and found something important: adding chemotherapy prolonged survival mainly in the first four months, and across the entire follow-up there was no statistically significant difference between dogs that got chemo and those that did not. The combination of conventional plus low-dose chemo did best, but the overall gains were, in the authors' own word, "modest."

The deeper reason is what chemotherapy is and is not. Chemo is a blunt instrument. It kills fast-dividing cells wherever it finds them, cancerous or healthy, which is why it comes with toxicity and why the dose cannot simply be pushed higher and higher. It can knock the cancer back, but it does not teach the body to keep fighting after the drug is gone. Against a cancer that has already scattered through the bloodstream, knocking it back for a few months is often all it can do.

This is exactly the ceiling that immunotherapy is designed to break through, and it is the subject of the next post in this series.

The one factor that matters most: stage

If there is a single thing that shapes the outlook for a dog with splenic hemangiosarcoma, it is the stage at diagnosis, meaning how far the cancer has already spread. In the largest study, clinical stage was the only factor significantly linked to survival. Veterinary oncologists group splenic HSA into three stages:

• Stage I: the tumor is confined to the spleen, with no rupture and no detectable spread.
• Stage II: the tumor has ruptured, or reached a nearby lymph node, but has not spread to distant organs.
• Stage III: the cancer has spread to distant sites such as the liver or lungs.

The difference between them is not subtle. In that same 59-dog study, according to PubMed, median survival was 345 days for Stage I, 93 days for Stage II, and 68 days for Stage III (Kim et al., 2007). A dog whose cancer was caught while it was still confined to the spleen lived about five times longer than one whose cancer had already spread by the time it was found.

Stage at diagnosis is the single biggest factor

Median survival by stage, splenic hemangiosarcoma (the same 59-dog study)

The practical takeaway is uncomfortable but useful: because stage dominates everything, finding hemangiosarcoma earlier is one of the few levers that reliably changes the outlook. That is why early detection is a running theme in this series, and a later post is devoted to it.

Why this cancer is so hard, in one idea

If you take away one concept, make it this. The treatments we can throw at the visible tumor, surgery and radiation, are local. They deal with cancer in one place. But hemangiosarcoma is a fundamentally systemic disease by the time we usually meet it, scattered through the body in deposits too small to see. Local tools cannot solve a whole-body problem, and the one systemic tool we have relied on, chemotherapy, is limited by its own toxicity.

What you want against a whole-body cancer is a whole-body treatment that can tell cancer cells apart from healthy ones. That is the promise of immunotherapy, and it is why so much of the new hemangiosarcoma research, the vaccines, the checkpoint drugs, the combinations, is aimed there.

What this means for your dog

If your dog has just been diagnosed, the numbers on this page are hard to read, and we are sorry. A few honest, practical points:

• Surgery is still usually the right first step for a bleeding splenic tumor. It stops a life-threatening emergency, and it buys the time in which everything else becomes possible.
• Stage drives the conversation. Ask your veterinary oncologist what stage your dog is, and what that specifically means for the options in front of you.
• Standard chemotherapy helps modestly. It is reasonable to pursue, and it is also reasonable to ask what newer approaches, alone or in combination, might add. That is what the next posts cover.
• If a vaccine or personalized approach is on the table, the tumor sample matters enormously. How the tissue is preserved at surgery determines what can be done with it later. We wrote a separate guide on preserving a tumor sample for exactly this reason.

Every decision here belongs to you and a licensed veterinary oncologist who has examined your dog. Our role is to help you understand the landscape well enough to ask good questions.

A note on sources

The framing of this series was prompted by a public educational webinar, "Hemangiosarcoma in Dogs: New Treatments, Research, and Hope," from the Canine Cancer Alliance, a nonprofit that funds canine cancer research. Every survival figure in this post, though, is cited to its original peer-reviewed study, and where a widely repeated number did not hold up against the primary literature, we left it out.